---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000047"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:06:27.733119+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%

## Summary
- GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.
- Net revenues $15.776B, up 9.1% reported (8.4% operational); Immunology $7.885B (+11.9%) led by Skyrizi $4.708B (+46.8%).
- Raises 2025 adjusted diluted EPS guidance to $10.61-$10.65 (from $10.38-$10.58); includes $2.05/share YTD IPR&D impact.
- Quarterly dividend increased 5.5% to $1.73/share, payable Feb 17, 2026 to holders of record Jan 16, 2026.
- Oncology $1.682B (-0.3%); Aesthetics $1.193B (-3.7%); Neuroscience $2.841B (+20.2%); Vraylar $934M, Botox Therapeutic $985M.

## SEC filing metadata
- accession: 0001551152-25-000047
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/0001551152-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20251031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000047
- JSON: https://secwatch.observer/filing/0001551152-25-000047.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.